Reglixane

Các tên gọi khác (1) :

JTT-501

Thuốc Gốc

Small Molecule

Reglixane, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials.

Dược Lực Học : Reglixane shows a hypoglycemic effect and also a stronger triglyceride-lowering effect than the thiazolidine-2,4-diones. In preclinical studies, reglixane has been shown to prevent several diabetic complications, such as cataract, nephropathy, and neuropathy.

Cơ Chế Tác Dụng : Reglixane, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials. Reglixane is an agonist of peroxisome proliferator-activated receptor (PPAR) gamma and alpha.

Chỉ Định : For the treatment of diabetes mellitus type 1 and 2.

Tài Liệu Tham Khảo Thêm

drugbank

http://www.drugbank.ca/drugs/DB04971

Bạn thấy hài lòng ?

Bạn chưa hài lòng ?

... loading